140 related articles for article (PubMed ID: 32919000)
1. Improving long circulation and procoagulant platelet targeting by engineering of hirudin prodrug.
Han HH; Zhang HT; Wang R; Yan Y; Liu X; Wang Y; Zhu Y; Wang JC
Int J Pharm; 2020 Nov; 589():119869. PubMed ID: 32919000
[TBL] [Abstract][Full Text] [Related]
2. Engineering a "three-in-one" hirudin prodrug to reduce bleeding risk: A proof-of-concept study.
Zhu Y; Han HH; Zhai L; Yan Y; Liu X; Wang Y; Lei L; Wang JC
J Control Release; 2021 Oct; 338():462-471. PubMed ID: 34481024
[TBL] [Abstract][Full Text] [Related]
3. Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics.
Dong X; Gu R; Zhu X; Gan H; Liu J; Jin J; Meng Z; Dou G
Eur J Pharm Sci; 2018 Aug; 121():166-177. PubMed ID: 29802897
[TBL] [Abstract][Full Text] [Related]
4. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
5. Effect of hirudin versus heparin on hemocompatibility of blood contacting biomaterials: an in vitro study.
Kopp R; Bernsberg R; Kashefi A; Mottaghy K; Rossaint R; Kuhlen R
Int J Artif Organs; 2005 Dec; 28(12):1272-7. PubMed ID: 16404704
[TBL] [Abstract][Full Text] [Related]
6. Self-regulated hirudin delivery for anticoagulant therapy.
Xu X; Huang X; Zhang Y; Shen S; Feng Z; Dong H; Zhang C; Mo R
Sci Adv; 2020 Oct; 6(41):. PubMed ID: 33036973
[TBL] [Abstract][Full Text] [Related]
7. Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner.
Peter K; Gupta A; Nordt T; Bauer S; Runge MS; Bode C
J Cardiovasc Pharmacol; 2003 Aug; 42(2):237-44. PubMed ID: 12883328
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin.
Jakubowski JA; Maraganore JM
Blood; 1990 Jan; 75(2):399-406. PubMed ID: 2294999
[TBL] [Abstract][Full Text] [Related]
9. RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection.
Li YR; Huang YN; Zhao B; Wu MF; Li TY; Zhang YL; Chen D; Yu M; Mo W
Acta Pharmacol Sin; 2020 Jun; 41(6):753-762. PubMed ID: 31949293
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided creation of AcAP5-derived and platelet targeted factor Xa inhibitors.
Zhu Y; Lin Y; Liu A; Shui M; Li R; Liu X; Hu W; Wang Y
Biochem Pharmacol; 2015 Jun; 95(4):253-62. PubMed ID: 25887920
[TBL] [Abstract][Full Text] [Related]
11. Platelet-Covered Nanocarriers for Targeted Delivery of Hirudin to Eliminate Thrombotic Complication in Tumor Therapy.
Zhang K; Ma Z; Li S; Zhang W; Foda MF; Zhao Y; Han H
ACS Nano; 2022 Nov; 16(11):18483-18496. PubMed ID: 36350264
[TBL] [Abstract][Full Text] [Related]
12. A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss.
Sheffield WP; Eltringham-Smith LJ; Bhakta V
BMC Biotechnol; 2018 Apr; 18(1):21. PubMed ID: 29621998
[TBL] [Abstract][Full Text] [Related]
13. In situ formed depot of elastin-like polypeptide-hirudin fusion protein for long-acting antithrombotic therapy.
Tian X; Feng M; Wei X; Cheng C; He K; Jiang T; He B; Gu Z
Proc Natl Acad Sci U S A; 2024 Mar; 121(11):e2314349121. PubMed ID: 38442174
[TBL] [Abstract][Full Text] [Related]
14. Hirudin and derivatives as anticoagulant agents.
Markwardt F
Thromb Haemost; 1991 Jul; 66(1):141-52. PubMed ID: 1926044
[No Abstract] [Full Text] [Related]
15. Recombinant hirudin as an anticoagulant during cardiac operations: experiments in a pig model.
Riess FC; Pötzsch B; Behr I; Jäger K; Rössing R; Bleese N; Schaper W; Müller-Berghaus G
Eur J Cardiothorac Surg; 1997 Apr; 11(4):739-45. PubMed ID: 9151047
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.
Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).
Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA
Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120
[TBL] [Abstract][Full Text] [Related]
18. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.
Zoldhelyi P; Webster MW; Fuster V; Grill DE; Gaspar D; Edwards SJ; Cabot CF; Chesebro JH
Circulation; 1993 Nov; 88(5 Pt 1):2015-22. PubMed ID: 8222093
[TBL] [Abstract][Full Text] [Related]
19. Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris.
Sheffield WP; Smith IJ; Syed S; Bhakta V
Blood Coagul Fibrinolysis; 2001 Sep; 12(6):433-43. PubMed ID: 11555696
[TBL] [Abstract][Full Text] [Related]
20. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa.
Al-Tamimi M; Grigoriadis G; Tran H; Paul E; Servadei P; Berndt MC; Gardiner EE; Andrews RK
Blood; 2011 Apr; 117(14):3912-20. PubMed ID: 21252089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
